The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma. In the case presented, the patient had a GBM but was allergic to Temodar so they had to try something different. They tried erltinib and Optune, which has resulted in stable disease for at least 9 months after radiation. It is only 1 case but shows brilliant thinking on the part of this patient's team. They chose Optune, which is the obvious choice, but since the patient overexpressed EGFR, they also added erlotinib. More research needs to be done on such combinations of Optune and therapies personalized to the patient!
ONC201 Investigator Meeting and Clinical Efficacy in H3 K27M-mutant Glioma to be Presented at Society for Neuro-Oncology Conference I am a little biased on this one as we gave them 3 grants - including our largest ever - to help get them to this point. They will be presenting 10 abstracts at next week's Society for Neuro-Oncology conference in New Orleans. This experimental drug - Onc-201 is the first of it's class - a DRD2/ DRD3 antagonist. Early results were very impressive, and we are hoping they present exciting news next week!
